



DIVERSITY, EQUITY AND INCLUSION IN CLINICAL TRIALS

©2022 Merck KGaA, Darmstadt, Germany or its affiliates. All rights reserved.

EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada.

US-NONO-00270
March 2022

**EMD
SERONO**

In the United States, people of color make up 43% of the population¹,

YET THERE IS SYSTEMATIC UNDER-REPRESENTATION IN CLINICAL TRIALS.

Only
8%

of clinical trial participants are **Black** despite making up

14%

of the US population²

Only
11%

of clinical trial participants are **Latino** despite making up

19%

of the US population²

WITHOUT DIVERSE REPRESENTATION, researchers are not able to identify or mitigate **different drug effects** in different populations.²

1. 2020 US census data. <https://www.census.gov/en.html>. Accessed March 11, 2022.

2. FDA Snapshot data: Participation in Clinical Trials by Subpopulation* for New Molecular Entities and Therapeutic Biologics Approved by FDA in 2020, <https://www.fda.gov/media/145718/download>. Accessed March 11, 2022.

There are four key barriers to participation in clinical trials for people of color...

1

Awareness

2


Access

3

Recruitment

4

Screening



Our approach to diversity, equity and inclusion in clinical trials

OUR Objective

To **better reflect** in our clinical trials and provide benefit to the **diverse patient populations** that are in need and would most likely use our drug(s) for treating their disease

Our focus includes, but is not limited to, **age, sex, gender, gender identity, race, ethnicity, religion, and their intersections**



[Click here](#)

OUR COMMITMENT

To **address key barriers and limitations** negatively impacting the diversity, equity and inclusion of minority populations in clinical trials with an end-to-end strategic mindset

WE USE FOUR KEY PILLARS

To create tactical and targeted efforts for an inclusive approach

1

**Partner with
HCPs who are
diverse or
provide
treatment
to diverse
communities**

2


**Invest in
community
education and
outreach –
spread
awareness**

3

**Facilitate
patient
participation
in clinical
research**

4


**Leverage
protocol
design and the
use of real-
world data**



OUR DIVERSITY, EQUITY & INCLUSION STRATEGY IS ALIGNED AND STRENGTHENED BY MULTIPLE INDUSTRY EFFORTS

An Inclusive, Overarching and Study Specific Approach

Diversity, Equity & Inclusion in Clinical Trials Strategy



FOUR KEY PILLARS

Identifying key tactical and targeted efforts for an inclusive approach



1 Partner with HCPs who are Diverse or Provide Care to Diverse Communities

Partner with healthcare providers who provide care to underserved and racial/ethnic populations to ensure comprehensive patient representation when developing treatments.



2 AWARENESS & COMMUNITY OUTREACH

Invest in community education, outreach and building trust within diverse communities to enhance clinical trial awareness and participation in the patient and medical community.



3 FACILITATE PATIENT PARTICIPATION IN CLINICAL RESEARCH

Ensure that trial participants represent target populations that are affected by the disease.



4 PROTOCOL DESIGN AND THE USE OF REAL WORLD DATA

Design inclusive clinical trials that follow internal and external guidance and best practices related to diversity of patients in clinical trials while utilizing real world data.



LET'S TALK!



How do we **shape our collaboration** in Diversity, Equity and Inclusion?

